Kriya Therapeutics Completes Renovation of Its Facility for Scalable Gene Therapy Manufacturing

Kriya Therapeutics, Inc., a fully integrated platform company pioneering novel technologies and therapeutics in gene therapy, today announced the completion of the renovation of its 51,000 square foot facility located in Research Triangle Park, North Carolina to support cGMP production of its expanding pipeline of gene therapies.

“This achievement is a testament to the industry leading caliber of talent at Kriya and the company’s ambitious vision to be a fully integrated innovator in gene therapy.”

“At Kriya we are focused on building fully integrated capabilities to support the design, development and manufacturing of gene therapies to address a range of rare and prevalent diseases,” said Shankar Ramaswamy, M.D., Co-Founder and Chief Executive Officer of Kriya. “With our state-of-the-art facility in Research Triangle Park, we are uniquely positioned to advance our proprietary manufacturing platform to deliver the highest quality of gene therapies at scale, from early research through commercialization.”

The facility will support the advancement of STRIPE™, Kriya’s proprietary high-efficiency manufacturing platform integrating advances in cell line technology and upstream and downstream process to achieve exponential reductions in production costs at scale. The facility includes capabilities to support vial-to-vial production of gene therapies – with in-house process development and analytical development labs, quality control testing, pilot production, fill/finish and multiple cGMP suites with the capacity to support the simultaneous production of material across products at up to 3,000L scale.

“It is remarkable that the Kriya team has been able to complete the renovation of this facility to support cGMP production of gene therapies since first taking occupancy of the building almost exactly one year ago. The speed at which we’ve been able to stand up this integrated facility has been incredible,” said Britt Petty, Chief Manufacturing Officer of Kriya. “This achievement is a testament to the industry leading caliber of talent at Kriya and the company’s ambitious vision to be a fully integrated innovator in gene therapy.”

About Kriya Therapeutics

Kriya Therapeutics is a fully integrated platform company pioneering novel technologies and therapeutics in gene therapy. The company aims to revolutionize how gene therapies are designed, developed and manufactured – improving speed to market and delivering significant reductions in the cost per dose. Kriya is built on two distinct technology platforms: its computationally enabled proprietary platform for rational vector design (SIRVE™) and its innovative high-efficiency manufacturing platform for scalable and low-cost production (STRIPE™). The company is advancing a deep and diversified pipeline of innovative gene therapies spanning rare and prevalent diseases in multiple therapeutic verticals, with current pipeline programs addressing metabolic, ophthalmic and oncologic diseases. With locations in Silicon Valley, Calif., and Research Triangle Park, N.C., Kriya was founded by pioneers in the biopharmaceutical industry and is backed by blue-chip life sciences and technology investors.